moxifloxacin has been researched along with aleglitazar in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (aleglitazar) | Trials (aleglitazar) | Recent Studies (post-2010) (aleglitazar) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 43 | 19 | 37 |
| Protein | Taxonomy | moxifloxacin (IC50) | aleglitazar (IC50) |
|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.019 | |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | 0.038 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bentley, D; Jordan, P; Ruf, T; Russell-Yarde, F; Sturm, S | 1 |
1 trial(s) available for moxifloxacin and aleglitazar
| Article | Year |
|---|---|
No evidence of QT prolongation with supratherapeutic doses of aleglitazar.
Topics: Adult; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Oxazoles; PPAR alpha; PPAR gamma; Quinolines; Thiophenes; Time Factors; Young Adult | 2012 |